Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo

Sheila Makiala; Daniel Mukadi; Anja De Weggheleire; Shino Muramatsu; Daisuke Kato; Koichi Inano; Fumio Gondaira; Masahiro Kajihara; Reiko Yoshida; Katendi Changula; Aaron Mweene; Placide Mbala-Kingebeni; Jean-Jacques Muyembe-Tamfum; Justin Masumu; Steve Ahuka; Ayato Takada

doi:10.3390/v11070589

Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo

Sheila Makiala, Daniel Mukadi, Anja De Weggheleire, Shino Muramatsu, Daisuke Kato, Koichi Inano, Fumio Gondaira, Masahiro Kajihara, Reiko Yoshida, Katendi Changula, Aaron Mweene, Placide Mbala-Kingebeni, Jean-Jacques Muyembe-Tamfum, Justin Masumu, Steve Ahuka, Ayato Takada

Neglected Tropical Diseases

Research output: Contribution to journal › A1: Web of Science-article › peer-review

89 Downloads (Pure)

Abstract

The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi(TM)-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi(TM)-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi(TM)-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi(TM)-Ebola for point-of-care diagnosis of EVD.

Original language	English
Article number	589
Journal	Viruses
Volume	11
Issue number	7
Number of pages	7
ISSN	1999-4915
DOIs	https://doi.org/10.3390/v11070589
Publication status	Published - 2019

Keywords

Ebola virus
EVD
rapid diagnostic test
immunochromatography
QuickNavi
DRC

Access to Document

10.3390/v11070589Licence: CC BY

2019viru0589Final published version, 303 KBLicence: CC BY

Cite this

Makiala, S., Mukadi, D., De Weggheleire, A., Muramatsu, S., Kato, D., Inano, K., Gondaira, F., Kajihara, M., Yoshida, R., Changula, K., Mweene, A., Mbala-Kingebeni, P., Muyembe-Tamfum, J.-J., Masumu, J., Ahuka, S., & Takada, A. (2019). Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo. Viruses, 11(7), Article 589. https://doi.org/10.3390/v11070589

@article{577a9da31a5149349abffa21b3cd638e,

title = "Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo",

abstract = "The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi(TM)-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi(TM)-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi(TM)-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi(TM)-Ebola for point-of-care diagnosis of EVD.",

keywords = "Ebola virus, EVD, rapid diagnostic test, immunochromatography, QuickNavi, DRC",

author = "Sheila Makiala and Daniel Mukadi and {De Weggheleire}, Anja and Shino Muramatsu and Daisuke Kato and Koichi Inano and Fumio Gondaira and Masahiro Kajihara and Reiko Yoshida and Katendi Changula and Aaron Mweene and Placide Mbala-Kingebeni and Jean-Jacques Muyembe-Tamfum and Justin Masumu and Steve Ahuka and Ayato Takada",

note = "FTX; DOAJ; (CC BY 4.0)",

year = "2019",

doi = "10.3390/v11070589",

language = "English",

volume = "11",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

Makiala, S, Mukadi, D, De Weggheleire, A, Muramatsu, S, Kato, D, Inano, K, Gondaira, F, Kajihara, M, Yoshida, R, Changula, K, Mweene, A, Mbala-Kingebeni, P, Muyembe-Tamfum, J-J, Masumu, J, Ahuka, S & Takada, A 2019, 'Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo', Viruses, vol. 11, no. 7, 589. https://doi.org/10.3390/v11070589

TY - JOUR

T1 - Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo

AU - Makiala, Sheila

AU - Mukadi, Daniel

AU - De Weggheleire, Anja

AU - Muramatsu, Shino

AU - Kato, Daisuke

AU - Inano, Koichi

AU - Gondaira, Fumio

AU - Kajihara, Masahiro

AU - Yoshida, Reiko

AU - Changula, Katendi

AU - Mweene, Aaron

AU - Mbala-Kingebeni, Placide

AU - Muyembe-Tamfum, Jean-Jacques

AU - Masumu, Justin

AU - Ahuka, Steve

AU - Takada, Ayato

N1 - FTX; DOAJ; (CC BY 4.0)

PY - 2019

Y1 - 2019

N2 - The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi(TM)-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi(TM)-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi(TM)-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi(TM)-Ebola for point-of-care diagnosis of EVD.

AB - The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi(TM)-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi(TM)-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi(TM)-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi(TM)-Ebola for point-of-care diagnosis of EVD.

KW - Ebola virus

KW - EVD

KW - rapid diagnostic test

KW - immunochromatography

KW - QuickNavi

KW - DRC

U2 - 10.3390/v11070589

DO - 10.3390/v11070589

M3 - A1: Web of Science-article

SN - 1999-4915

VL - 11

JO - Viruses

JF - Viruses

IS - 7

M1 - 589

ER -

Clinical evaluation of QuickNavi(TM)-Ebola in the 2018 outbreak of Ebola virus disease in the Democratic Republic of the Congo

Abstract

Keywords

Access to Document

Fingerprint

Cite this